A Phase 3 interventional study of ZOSTAVAX in Herpes Zoster, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-01-09.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing Chickenpox Vaccine in Herpes Zoster — none open to participants now, none under way, none of them phase 3. Chickenpox Vaccine · Herpes Zoster.
Among the 29 studies testing Chickenpox Vaccine in Herpes Zoster, this one is the 9th largest by enrollment, is one of 4 that started in 2011, is one of 9 in phase 3, and was the 15th registered.
299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.
Browse Herpes Zoster studies →None of the 29 studies testing Chickenpox Vaccine in Herpes Zoster is open now. The open studies under Herpes Zoster, anywhere →
Chickenpox Vaccine: first FDA approval 1995 (Varivax). What it is approved for, and how studies give it, is on its page →
Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.
This study: 50 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 9 · Phase 4 8
First in 2001; this study’s year is marked. 4 started in 2011.
This study's enrollment of 354 is above the median of 160 across 247 interventional studies indexed under Herpes Zoster.
Median enrollment 160 across the 29 interventional studies. Of the 28 that completed or were terminated, 20 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 29 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
27 studies in Herpes Zoster by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 26 finished, 24 (92%) have results posted.
Among the 27 studies in Herpes Zoster by Merck & Co., Inc, this one is the 12th largest by enrollment of the 25 interventional ones that give a count, is one of 4 that started in 2011, is one of 14 in phase 3, and was the 19th registered.
Merck & Co., Inc’s Herpes Zoster studies by the year they started, since 1995.
None of the studies under way reaches primary completion within a year.
Among the 29 studies testing Chickenpox Vaccine in Herpes Zoster, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 27 in Herpes Zoster:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
PRIMARY OBJECTIVES
Two co-primary objectives are:
SECONDARY OBJECTIVES
Immunogenicity objectives
Safety objective
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single dose of 0.65 mL via IM injection
Biological: ZOSTAVAX
Single dose of 0.65 mL via SC injection
Biological: ZOSTAVAX
1 dose 0.65 mL
Also known as: V211
Geometric Mean Titre (GMT) of Varicella Zoster Virus (VZV) Antibodies 4 Weeks Post-vaccination
Blood samples taken at 4 weeks post vaccination to determine the geometric mean titre (GMT) of VZV antibodies via Glycoprotein Enzyme Linked Immunosorbent Assay (gpELISA).
Time frame: 4 week post-vaccination
Geometric Mean Fold Rise (GMFR) in VZV Antibody Titre: IM Route
Blood sample taken at predose (Day 0) and 4 weeks post vaccination to determine the geometric mean titre (GMT) of VZV antibodies via gpELISA. The GMFR was calculated as GMT Post-dose/GMT Pre-vaccination
Time frame: Pre-vaccination (Day 0) and 4 week post-vaccination
Geometric Mean Fold Rise (GMFR) in VZV Antibody Titre: SC Route
Blood sample taken at predose (Day 0) and 4 weeks post vaccination to determine the geometric mean titre (GMT) of VZV antibodies via gpELISA. The GMFR was calculated as GMT Post-vaccination/GMT Pre-vaccination
Time frame: Pre-vaccination (Day 0) and 4 week post-vaccination
Geometric Mean Count (GMCs) of VZV Interferon Gamma ((IFN-γ) Enzyme-Linked ImmunoSpot (ELISPOT) Antibodies
Blood samples taken 4 weeks post-vaccination to determine the IFN-γ ELISPOT GMC's. Results were reported as ELISPOT count/10\^6 Peripheral Blood Mononuclear Cells (PBMC)
Time frame: 4 week post-vaccination
Geometric Mean Fold Rise (GMFR) of IFN-γ ELISPOT Antibodies
Blood samples taken pre-vaccination and 4 weeks post-vaccination to determine the IFN-γ ELISPOT GMFR.
Time frame: Pre-vaccination (Day 0) and 4 week post-vaccination
Percentage of Participants Who Report at Least 1 Injection-site Adverse Reaction
Participants entered data into daily diary card regarding previously identified possible injection site reactions of erythema, injection site swelling or injection site pain for 1st 4 days post-vaccination. Additionally, injection site reactions not prompted on diary card (unsolicited) were collected up 28 days post-vaccination. All injection site reactions (solicited or unsolicited) were recorded.
Time frame: up to 28 days after vaccination
Percentage of Participants Who Report at Least 1 Systemic Adverse Event
An adverse event (AE) was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Adverse events that were considered systemic (not localized) were summarized. These events included rashes of interest: i.e. Varicella, Varicella-like rashes, Herpes zoster or shingles and Herpes zoster-like rashes and other systemic adverse events.
Time frame: up to Day 28 after vaccination
Percentage of Participants Who Report at Least 1 Serious Adverse Event
A serious adverse event (SAE) is any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an "other important medical event" based on medical judgement. The percentage of participants who reported an SAE within 35 days of vaccination were recorded.
Time frame: up to 35 days after vaccination
| Milestone | ZOSTAVAX Intramuscular (IM) Route | ZOSTAVAX Subcutaneous (SC) Route |
|---|---|---|
| Started | 177 | 177 |
| Vaccinated | 176 | 177 |
| Completed | 176 | 177 |
| Not completed | 1 | 0 |
| Withdrew: History of herpes zoster (hz) | 1 | 0 |
Blood samples taken at 4 weeks post vaccination to determine the geometric mean titre (GMT) of VZV antibodies via Glycoprotein Enzyme Linked Immunosorbent Assay (gpELISA).
| gpELISA units/mL | ZOSTAVAX Intramuscular (IM) Route | ZOSTAVAX Subcutaneous (SC) Route |
|---|---|---|
| Geometric Mean Titre (GMT) of Varicella Zoster Virus (VZV) Antibodies 4 Weeks Post-vaccination | 395.3 (350.6 to 445.6) | 391.7 (348.9 to 439.7) |
Blood sample taken at predose (Day 0) and 4 weeks post vaccination to determine the geometric mean titre (GMT) of VZV antibodies via gpELISA. The GMFR was calculated as GMT Post-dose/GMT Pre-vaccination
| Ratio | ZOSTAVAX Intramuscular (IM) Route |
|---|---|
| Geometric Mean Fold Rise (GMFR) in VZV Antibody Titre: IM Route | 2.7 (2.4 to 3.0) |
Blood sample taken at predose (Day 0) and 4 weeks post vaccination to determine the geometric mean titre (GMT) of VZV antibodies via gpELISA. The GMFR was calculated as GMT Post-vaccination/GMT Pre-vaccination
| Ratio | ZOSTAVAX Subcutaneous (SC) Route |
|---|---|
| Geometric Mean Fold Rise (GMFR) in VZV Antibody Titre: SC Route | 2.5 (2.2 to 2.8) |
Blood samples taken 4 weeks post-vaccination to determine the IFN-γ ELISPOT GMC's. Results were reported as ELISPOT count/10\^6 Peripheral Blood Mononuclear Cells (PBMC)
| ELISPOT count/10^6 PBMC | ZOSTAVAX Intramuscular (IM) Route | ZOSTAVAX Subcutaneous (SC) Route |
|---|---|---|
| Geometric Mean Count (GMCs) of VZV Interferon Gamma ((IFN-γ) Enzyme-Linked ImmunoSpot (ELISPOT) Antibodies | 209.8 (175.2 to 251.3) | 195.7 (161.9 to 236.6) |
Blood samples taken pre-vaccination and 4 weeks post-vaccination to determine the IFN-γ ELISPOT GMFR.
| Ratio | ZOSTAVAX Intramuscular (IM) Route | ZOSTAVAX Subcutaneous (SC) Route |
|---|---|---|
| Geometric Mean Fold Rise (GMFR) of IFN-γ ELISPOT Antibodies | 3.3 (2.8 to 3.9) | 3.4 (2.7 to 4.3) |
Participants entered data into daily diary card regarding previously identified possible injection site reactions of erythema, injection site swelling or injection site pain for 1st 4 days post-vaccination. Additionally, injection site reactions not prompted on diary card (unsolicited) were collected up 28 days post-vaccination. All injection site reactions (solicited or unsolicited) were recorded.
| Percentage of Participants | ZOSTAVAX Intramuscular (IM) Route | ZOSTAVAX Subcutaneous (SC) Route |
|---|---|---|
| Percentage of Participants Who Report at Least 1 Injection-site Adverse Reaction | 34.1 (27.1 to 41.6) | 64.4 (56.9 to 71.4) |
An adverse event (AE) was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Adverse events that were considered systemic (not localized) were summarized. These events included rashes of interest: i.e. Varicella, Varicella-like rashes, Herpes zoster or shingles and Herpes zoster-like rashes and other systemic adverse events.
| Percentage of Participants | ZOSTAVAX Intramuscular (IM) Route | ZOSTAVAX Subcutaneous (SC) Route |
|---|---|---|
| Percentage of Participants Who Report at Least 1 Systemic Adverse Event | 23.3 (17.3 to 30.2) | 22.6 (16.7 to 29.5) |
A serious adverse event (SAE) is any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an "other important medical event" based on medical judgement. The percentage of participants who reported an SAE within 35 days of vaccination were recorded.
| Percentage of Participants | ZOSTAVAX Intramuscular (IM) Route | ZOSTAVAX Subcutaneous (SC) Route |
|---|---|---|
| Percentage of Participants Who Report at Least 1 Serious Adverse Event | 0.6 (NA to 3.1) | 1.1 |
Collected over up to 35 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ZOSTAVAX Intramuscular (IM) Route | — | 1/176 (0.6%) | 59/176 (33.5%) |
| ZOSTAVAX Subcutaneous (SC) Route | — | 2/177 (1.1%) | 112/177 (63.3%) |
| Event | ZOSTAVAX Intramuscular (IM) Route | ZOSTAVAX Subcutaneous (SC) Route |
|---|---|---|
| Hernia obstructiveGeneral disorders | 1/176 | 0/177 |
| Humerus fractureInjury, poisoning and procedural complications | 0/176 | 1/177 |
| Deep vein thrombosisVascular disorders | 0/176 | 1/177 |
| Event | ZOSTAVAX Intramuscular (IM) Route | ZOSTAVAX Subcutaneous (SC) Route |
|---|---|---|
| Injection site erythemaGeneral disorders | 29/176 | 94/177 |
| Injection site painGeneral disorders | 46/176 | 70/177 |
| Injection site swellingGeneral disorders | 24/176 | 67/177 |
| Injection site pruritusGeneral disorders | 3/176 | 11/177 |
| Age, Customized(Participants) | ZOSTAVAX Intramuscular (IM) Route | ZOSTAVAX Subcutaneous (SC) Route | Total |
|---|---|---|---|
| 50-59 years of age | 81 | 82 | 163 |
| 60-69 years of age | 56 | 55 | 111 |
| ≥70 years of age | 40 | 40 | 80 |
| Sex: Female, Male(Participants) | ZOSTAVAX Intramuscular (IM) Route | ZOSTAVAX Subcutaneous (SC) Route | Total |
|---|---|---|---|
| Female | 98 | 97 | 195 |
| Male | 79 | 80 | 159 |
| Age at Vaccination(Years of Age) | ZOSTAVAX Intramuscular (IM) Route | ZOSTAVAX Subcutaneous (SC) Route | Total |
|---|---|---|---|
| Mean | 62.6 ± 8.3 | 62.6 ± 8.5 | 62.6 ± 8.4 |
No study locations are listed for this record.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Jun 2011 to primary completion in Oct 2012, 15 months.
Results were first posted in Nov 2017, 5 years 1 month after primary completion.
Of 33 industry-sponsored phase 3 interventional studies under Herpes Zoster, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 45. This study's 15 months is close to that.
Counting every sponsor, half of 40 studies reached it within 16 months; a quarter within 10 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Chickenpox Vaccine